Search

Your search keyword '"RAGO, ANNA"' showing total 478 results
Start Over Author "RAGO, ANNA"
478 results on '"RAGO, ANNA"'

51. Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry

Author

Russo, Vincenzo, primary, D'Andrea, Antonello, additional, De Vivo, Stefano, additional, Rago, Anna, additional, Manzo, Gianluca, additional, Bocchetti, Antonio, additional, Papa, Andrea Antonio, additional, Giordano, Valerio, additional, Ammendola, Ernesto, additional, Sarubbi, Berardo, additional, Golino, Paolo, additional, D'Onofrio, Antonio, additional, and Nigro, Gerardo, additional

Published
2022
Full Text
View/download PDF

57. Edoxaban (LIXIANA®) in the treatment of venous thromboembolism

Author

Bottino, Roberta, primary, Carbone, Andreina, additional, Liccardo, Biagio, additional, D’Andrea, Antonello, additional, Rago, Anna, additional, Papa, Andrea Antonio, additional, Spaccarotella, Carmen, additional, Golino, Paolo, additional, Nigro, Gerardo, additional, and Russo, Vincenzo, additional

Published
2021
Full Text
View/download PDF

60. Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study

Author

Rago, Anna, primary, Pezzullo, Enrica, additional, Malvezzi Caracciolo d'Aquino, Marco, additional, Scognamiglio, Gabriella, additional, Caso, Valentina Maria, additional, Martone, Francesco, additional, Attena, Emilio, additional, Parisi, Valentina, additional, D'Onofrio, Antonio, additional, Golino, Paolo, additional, Nigro, Gerardo, additional, and Russo, Vincenzo, additional

Published
2021
Full Text
View/download PDF

61. Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study

Author

Rago,Anna, Pezzullo,Enrica, Malvezzi Caracciolo d'Aquino,Marco, Scognamiglio,Gabriella, Caso,Valentina Maria, Martone,Francesco, Attena,Emilio, Parisi,Valentina, D'Onofrio,Antonio, Golino,Paolo, Nigro,Gerardo, Russo,Vincenzo, Rago,Anna, Pezzullo,Enrica, Malvezzi Caracciolo d'Aquino,Marco, Scognamiglio,Gabriella, Caso,Valentina Maria, Martone,Francesco, Attena,Emilio, Parisi,Valentina, D'Onofrio,Antonio, Golino,Paolo, Nigro,Gerardo, and Russo,Vincenzo

Abstract

Anna Rago,1 Enrica Pezzullo,1 Marco Malvezzi Caracciolo d’Aquino,1 Gabriella Scognamiglio,1 Valentina Maria Caso,2 Francesco Martone,3 Emilio Attena,4 Valentina Parisi,5 Antonio D’Onofrio,4 Paolo Golino,1 Gerardo Nigro,1 Vincenzo Russo1 1Department of Cardiology, Monaldi Hospital, Naples, Italy; 2Department of Medical Translational Sciences, University of the Study of Campania “Luigi Vanvitelli”, Naples, Italy; 3Clinical Biochemistry Unit, Monaldi Hospital, Naples, Italy; 4Departmental Unit of Electrophysiology, Monaldi Hospital, Naples, Italy; 5Department of Translational Medical Sciences, University of Naples Federico II, Naples, ItalyCorrespondence: Vincenzo RussoDepartment of Medical Transalational Sciences, University of Campania - Monaldi Hospital, Via Leonardo Bianchi, Naples, 80131, ItalyFax +39-0817587482Email v.p.russo@libero.itAim: The aim of the present study was to assess the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients undergoing electrical cardioversion (EC).Methods: A propensity score-matched analysis was performed in order to identify two homogeneous groups including AF patients on NOACs and VKAs treatment scheduled for EC. The primary safety endpoint was major bleeding. The composite of stroke, transient ischemic attack (TIA) and systemic embolism (SE) was the primary effectiveness endpoint. The discontinuation rate of anticoagulant therapy was assessed.Results: A total of 495 AF patients on NOACs therapy and scheduled for EC were compared to 495 VKAs recipients. No statistically significant differences in the incidence of both major bleeding (1.01% versus 1.4%; P= 0.5) and thromboembolic events (0.6% versus 0.8%; P= 0.7) were observed during a mean follow-up of 15 ± 3 months. The discontinuation rate of NOACs was significantly lower compared to VKAs (1.6% versus 3.6%, P=0.04).Conclusion: We

Published
2021

65. Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the predictive role of programmed ventricular stimulation.

Author

Russo, Vincenzo, Papa, Andrea Antonio, Rago, Anna, Ciardiello, Carmine, Martino, Anna Maria, Stazi, Alessandra, Golino, Paolo, Calò, Leonardo, and Nigro, Gerardo

Subjects
RESEARCH, CLINICAL trials, RESEARCH methodology, IMPLANTABLE cardioverter-defibrillators, EVALUATION research, VENTRICULAR tachycardia, COMPARATIVE studies, MYOTONIA atrophica, CARDIAC arrest, LONGITUDINAL method, DISEASE complications
Abstract

Aims: Myotonic dystrophy type 1 (DM1) predisposes to the development of life-threatening arrhythmias and sudden cardiac death. Our study aimed to evaluate the prognostic value of programmed ventricular stimulation (PVS) in DM1 patients with conduction system disease.Methods and Results: Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) is a double-arm non-randomized interventional prospective study. Myotonic dystrophy type 1 patients with permanent cardiac pacing indication were eligible for the inclusion. The study population underwent to pacemaker (PM) or implantable cardioverter-defibrillator (ICD) implantation according to the inducibility of ventricular tachyarrhythmias at PVS. Primary endpoint of the study was a composite of appropriate ICD therapy and cardiac arrhythmic death. The secondary study endpoint was all-cause mortality. Seventy-two adult-onset DM1 patients (51 ± 12 years; 39 male) were enrolled in the study. A ventricular tachyarrhythmia was induced in 25 patients (34.7%) at PVS (PVS+) who underwent dual chambers ICD implantation. The remaining 47 patients (65.3%) without inducible ventricular tachyarrhythmia (PVS-) were treated with dual-chamber PM. During an average observation period of 44.7 ± 10.2 months, nine patients (12.5%) met the primary endpoint, four in the ICD group (16%) and five (10.6%) in the PM group. Thirteen patients died (18.5%), 2 in the ICD group (8%) and 11 in PM group (23.4%). The Kaplan-Meier analysis did not show a significantly different risk of both primary and secondary endpoint event rates between the two groups.Conclusions: The inducibility of ventricular tachyarrhythmias has shown a limited value in the arrhythmic risk stratification among DM1 patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

68. Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown

Author

Russo, Vincenzo, primary, Rapacciuolo, Antonio, additional, Pafundi, Pia Clara, additional, de Divitiis, Marcello, additional, Volpicelli, Mario, additional, Ruocco, Antonio, additional, Rago, Anna, additional, Uran, Carlo, additional, Nappi, Felice, additional, Attena, Emilio, additional, Chianese, Raffaele, additional, Esposito, Francesca, additional, Del Giorno, Giuseppe, additional, D’Andrea, Antonello, additional, Ducceschi, Valentino, additional, Russo, Giovanni, additional, Ammendola, Ernesto, additional, Carbone, Angelo, additional, Covino, Gregorio, additional, Manzo, Gianluca, additional, Montella, Gianna Maria, additional, D’Onofrio, Antonio, additional, and Nigro, Gerardo, additional

Published
2021
Full Text
View/download PDF

78. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study

Author

Russo, Vincenzo, primary, Attena, Emilio, additional, Rago, Anna, additional, Melillo, Enrico, additional, Di Micco, Pierpaolo, additional, Papa, Andrea Antonio, additional, Napolitano, Giovanni, additional, D’Onofrio, Antonio, additional, Golino, Paolo, additional, and Nigro, Gerardo, additional

Published
2020
Full Text
View/download PDF

79. The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator

Author

Russo, Vincenzo, primary, Bottino, Roberta, additional, Rago, Anna, additional, Papa, Andrea Antonio, additional, Liccardo, Biagio, additional, Proietti, Riccardo, additional, Manna, Vincenzo, additional, Golino, Paolo, additional, D’Onofrio, Antonio, additional, and Nigro, Gerardo, additional

Published
2020
Full Text
View/download PDF

86. Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation

Author

Russo,Vincenzo, Paccone,Andrea, Rago,Anna, Maddaloni,Valeria, Iafusco,Dario, Proietti,Riccardo, Atripaldi,Umberto, D'Onofrio,Antonio, Golino,Paolo, Nigro,Gerardo, Russo,Vincenzo, Paccone,Andrea, Rago,Anna, Maddaloni,Valeria, Iafusco,Dario, Proietti,Riccardo, Atripaldi,Umberto, D'Onofrio,Antonio, Golino,Paolo, and Nigro,Gerardo

Abstract

Vincenzo Russo,1 Andrea Paccone,2 Anna Rago,1 Valeria Maddaloni,3 Dario Iafusco,4 Riccardo Proietti,5 Umberto Atripaldi,3 Antonio D’Onofrio,1 Paolo Golino,1 Gerardo Nigro1 1Chair of Cardiology, University of Campania “Luigi Vanvitelli”- Monaldi Hospital, Naples, Italy; 2Chair of Cardiology, University of Bari “Aldo Moro”, Bari, Italy; 3Chemical Biochemistry Unit, Monaldi Hospital, Naples, Italy; 4Department of Pediatrics, University of Campania “Luigi Vanvitelli”, Naples, Italy; 5Chair of Cardiology, University of Padua, Padua, ItalyCorrespondence: Vincenzo RussoChair of Cardiology, University of Campania “Luigi Vanvitelli”-Monaldi Hospital, Via Leonardo Bianchi, Naples 80126, ItalyTel +39 0817062355Email v.p.russo@libero.itAbstract: We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial determinations of apixaban plasma concentration (at 2, 6, 12, 24 hrs after intake) showing drug levels within reference range, even when the patient lose weight.Keywords: atrial fibrillation, obesity, non-vitamin k oral anticoagulant, plasma levels, apixaban, weight loss

Published
2020

87. Erratum: Management of Bradyarrhythmias in Heart Failure: A Tailored Approach (Adv Exp Med Biol- Advances in Internal Medicine, 10.1007/5584_2017_136)

Author

Masarone, Daniele, Ammendola, Ernesto, Rago, Anna, Gravino, Rita, Salerno, Gemma, Rubino, Marta, Marrazzo, Tommaso, Molino, Antonio, Calabrò, Paolo, Pacileo, Giuseppe, Limongelli, Giuseppe, Masarone, Daniele, Ammendola, Ernesto, Rago, Anna, Gravino, Rita, Salerno, Gemma, Rubino, Marta, Marrazzo, Tommaso, Molino, Antonio, Calabrò, Paolo, Pacileo, Giuseppe, and Limongelli, Giuseppe

Published
2018

88. Edoxaban (LIXIANA®) in the treatment of venous thromboembolism.

Author

Bottino, Roberta, Carbone, Andreina, Liccardo, Biagio, D'Andrea, Antonello, Rago, Anna, Papa, Andrea Antonio, Spaccarotella, Carmen, Golino, Paolo, Nigro, Gerardo, and Russo, Vincenzo

Abstract

Standard therapy for venous thromboembolism (VTE) includes the use of heparins and vitamin K antagonists. Randomized clinical trials have shown that non-vitamin K oral anticoagulants are as effective and safe as standard therapy in VTE treatment, with an improved pharmacological profile. Edoxaban, a direct inhibitor of factor Xa, has demonstrated noninferiority to standard therapy for the treatment of VTE, preserving a high safety profile even in long-term therapy, in frail patients and in severe clinical presentations. The present paper focuses on the role of edoxaban in VTE treatment, from general population to cancer patients, presenting the available data from randomized clinical trials and real world, to discuss edoxaban use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

89. Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

Author

Russo, Vincenzo, Melillo, Enrico, Papa, Andrea A., Rago, Anna, Chamberland, Celeste, and Nigro, Gerardo

Subjects
Article Subject
Abstract

Beta-thalassemias are a group of inherited, autosomal recessive diseases, characterized by reduced or absent synthesis of beta-globin chains of the hemoglobin tetramer, resulting in variable phenotypes, ranging from clinically asymptomatic individuals to severe anemia. Three main forms have been described: heterozygotes, homozygotes β+, and homozygotes β°. Beta-thalassemia major (β-TM), the most serious form, is characterized by an absent synthesis of globin chains that are essential for hemoglobin formation, causing chronic hemolytic anemia. Cardiac complications represent a leading cause of mortality in β-TM patients, although an important and progressive increase of life expectancy has been demonstrated after the introduction of chelating therapies. Iron overload is the primary factor of cardiac damage resulting in thalassemic cardiomyopathy, in which diastolic dysfunction usually happens before systolic impairment and overt heart failure (HF). Although iron-induced cardiomyopathy is slowly progressive and it usually takes several decades for clinical and laboratory features of cardiac dysfunction to manifest, arrhythmias or sudden death may be present without signs of cardiac disease and only if myocardial siderosis is present. Careful analysis of electrocardiograms and other diagnostic tools may help in early identification of high-risk β-TM patients for arrhythmias and sudden cardiac death.

Published
2019
Full Text
View/download PDF

91. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study

Author

Russo, Vincenzo, primary, Attena, Emilio, additional, Di Maio, Marco, additional, Mazzone, Carmine, additional, Carbone, Andreina, additional, Parisi, Valentina, additional, Rago, Anna, additional, D’Onofrio, Antonio, additional, Golino, Paolo, additional, and Nigro, Gerardo, additional

Published
2019
Full Text
View/download PDF

92. Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study

Author

Russo, Vincenzo, primary, Rago, Anna, additional, Proietti, Riccardo, additional, Attena, Emilio, additional, Rainone, Carmen, additional, Crisci, Mario, additional, Papa, Andrea Antonio, additional, Calabrò, Paolo, additional, D’Onofrio, Antonio, additional, Golino, Paolo, additional, and Nigro, Gerardo, additional

Published
2019
Full Text
View/download PDF

93. Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C

Author

DURANTE MANGONI, Emanuele, Parrella, Antonio, Vitrone, Martina, Rago, Anna, Pafundi, Pia Clara, NIGRO, Gerardo, UTILI, Riccardo, Russo, Vincenzo, DURANTE MANGONI, Emanuele, Parrella, Antonio, Vitrone, Martina, Rago, Anna, Pafundi, Pia Clara, Nigro, Gerardo, Utili, Riccardo, and Russo, Vincenzo

Subjects
direct antiviral agent, electrocardiography, hepatitis C, arrhythmia, sofosbuvir
Abstract

Recently, several cases of symptomatic, sometimes fatal bradycardia during the first days of direct-acting antiviral (DAA) (eg, sofosbuvir [SOF]) administration have been reported. We analyzed in detail electrocardiographic (ECG) changes during SOF- or non-SOF-based chronic hepatitis C (CHC) treatment, specifically focusing on bradyarrhythmias. All 39 consecutive patients treated at our center with any interferon-free regimen between June and December 2015 were included in this study (26 SOF-based therapy vs 13 no-SOF interferon-free regimens). ECG tracings were obtained from all patients the first day of treatment and after 7, 14, and 28 days. ECG parameters (P-wave, QRS, QT interval, JT interval, T(apex) -T(end) interval duration) were compared between the 2 groups at baseline and at the 3 different time points during antiviral therapy. There were no cases of symptomatic bradycardia/syncope. In the SOF group, QTc duration rose after 1 week (from 424.3 to 431.2 milliseconds; P = .013) and returned to baseline during therapy. QT dispersion dropped since week 1 (from 85.6 to 67.2 milliseconds) and remained significantly reduced until the end of the observation period (72.9 msec) (P = .003). JT dispersion reduced up to week 2 (P = .010) and returned to baseline at week 4; in the no-SOF group, QRS dispersion transiently reduced (from 41 to 34.5 milliseconds, day 7). No other significant changes were observed in the remaining parameters. In CHC patients treated with SOF and other DAAs, ECG parameter changes were mild and/or transient and did not translate into clinically significant electrophysiological effects in the absence of amiodarone coadministration. Recently, several cases of symptomatic, sometimes fatal bradycardia during the first days of direct-acting antiviral (DAA) (eg, sofosbuvir [SOF]) administration have been reported. We analyzed in detail electrocardiographic (ECG) changes during SOF- or non-SOF-based chronic hepatitis C (CHC) treatment, specifically focusing on bradyarrhythmias. All 39 consecutive patients treated at our center with any interferon-free regimen between June and December 2015 were included in this study (26 SOF-based therapy vs 13 no-SOF interferon-free regimens). ECG tracings were obtained from all patients the first day of treatment and after 7, 14, and 28 days. ECG parameters (P-wave, QRS, QT interval, JT interval, T-apex-T-end interval duration) were compared between the 2 groups at baseline and at the 3 different time points during antiviral therapy. There were no cases of symptomatic bradycardia/syncope. In the SOF group, QTc duration rose after 1 week (from 424.3 to 431.2 milliseconds; P = .013) and returned to baseline during therapy. QT dispersion dropped since week 1 (from 85.6 to 67.2 milliseconds) and remained significantly reduced until the end of the observation period (72.9 msec) (P = .003). JT dispersion reduced up to week 2 (P = .010) and returned to baseline at week 4; in the no-SOF group, QRS dispersion transiently reduced (from 41 to 34.5 milliseconds, day 7). No other significant changes were observed in the remaining parameters. In CHC patients treated with SOF and other DAAs, ECG parameter changes were mild and/or transient and did not translate into clinically significant electrophysiological effects in the absence of amiodarone coadministration.

Published
2017

97. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience

Author

Attena, Emilio, primary, Mazzone, Carmine, primary, Esposito, Francesca, primary, Parisi, Valentina, primary, Bancone, Ciro, primary, Rago, Anna, primary, Nigro, Gerardo, primary, Sangiuolo, Raffaele, primary, D' Onofrio, Antonio, primary, and Russo, Vincenzo, additional

Published
2018
Full Text
View/download PDF

98. Chronic Apical and Nonapical Right Ventricular Pacing in Patients with High-Grade Atrioventricular Block: Results of the Right Pace Study

Author

Muto, Carmine, primary, Calvi, Valeria, additional, Botto, Giovanni Luca, additional, Pecora, Domenico, additional, Porcelli, Daniele, additional, Costa, Alessandro, additional, Ciaramitaro, Gianfranco, additional, Airò Farulla, Riccardo, additional, Rago, Anna, additional, Calvanese, Raimondo, additional, Baratto, Marco Tullio, additional, Reggiani, Albino, additional, Giammaria, Massimo, additional, Patané, Santina, additional, Campari, Monica, additional, Valsecchi, Sergio, additional, and Maglia, Giampiero, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results